CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting

Mittwoch, 06.11.2019 15:10 von PR Newswire - Aufrufe: 41

PR Newswire

SEATTLE, Nov. 6, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7- 10, 2019 in Orlando, Florida.

The details of the oral presentation are as follows:

Abstract Title: Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
Session Number: 634
Session Name: Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies
Session Date: Monday, December 9, 2019
Session Time: 10:30 AM - 12:00 PM
Presentation Time: 10:30 AM
Publication Number: 667
Location: Orange County Convention Center, W311EFGH  

The details of the poster presentations are as follows:

Abstract Title: The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden
Session Number: 634
Session Name: Myeloproliferative Syndromes: Clinical: Poster I
Date: Saturday, December 7, 2019
Presentation Time: 5:30 PM - 7:30 PM
Publication Number: 1674
Location: Orange County Convention Center, Hall B

Abstract Title: Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)
Session Number: 634
Session Name: Myeloproliferative Syndromes: Clinical: Poster III 
Date: Monday, December 9, 2019 
Presentation Time: 6:00 PM - 8:00 PM 
Publication Number: 4175 
Location: Orange County Convention Center, Hall B

Abstract Title: Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
Session Number: 634
Session Name: Myeloproliferative Syndromes: Clinical: Poster III
Date: Monday, December 9, 2019
Presentation Time: 6:00 PM - 8:00 PM 
Publication Number: 4195
Location: Orange County Convention Center, Hall B

Abstract Title: Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib
Session Number: 635
Session Name: Myeloproliferative Syndromes: Basic Science: Poster III
Date: Monday, December 9, 2019
Presentation Time: 6:00 PM - 8:00 PM
Publication Number: 4214
Location: Orange County Convention Center, Hall B

A copy of each abstract is available here.

About CTI BioPharma Corp.
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular, we are focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington.

"CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan Meyers
+212-600-1902
cti@argotpartners.com

 

Cision View original content:http://www.prnewswire.com/news-releases/cti-biopharma-announces-presentations-at-the-61st-american-society-of-hematology-meeting-300952889.html

SOURCE CTI BioPharma Corp.

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Kurse

  
1,322
-9,45%
CTI BioPharma Chart